+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA



Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA



Annals of Surgery 230(4): 466-70; Discussion 470-2



To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad(GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047379842

Download citation: RISBibTeXText

PMID: 10522716


Related references

Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Human Gene Therapy 24(2): 203-208, 2013

Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100(5): 468-474, 1999

Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease - 12-month follow-up: Angiogenic gene therapy. Journal of Internal Medicine 250(5): 373-381, 2001

Safety of direct myocardial VEGF121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery. Circulation 98(17 Suppl. ): I321, 1998

Video assisted epicardial delivery of angiogenic gene therapy to the human myocardium utilizing an adenovirus vector encoding for VEGF121. Circulation 100(18 Suppl. ): I 770, 1999

The value of angiogenic therapy with intramyocardial administration of basic fibroblast growth factor to treat severe coronary artery disease. Annals of Thoracic and Cardiovascular Surgery 16(3): 174-180, 2010

Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. American Journal of Cardiology 92(9b): 24n-31n, 2003

Direct myocardial gene transfer of VEGF165 in patients with end-stage coronary artery disease 12-Month results of a phase I/II clinical trial. Journal of the American College of Cardiology 37(2 Suppl. A): 285A, 2001

Arteriogenesis induced by intramyocardial recombinant adeno-associated virus vector encoding human CD151 cDNA gene transfer in swines with coronary artery occlusion. Zhonghua Xin Xue Guan Bing Za Zhi 37(6): 537-541, 2009

Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. American Journal of Cardiology 90(5): 512-516, 2002

Phase I study of direct administration of a replication deficient adenovirus vector containing vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Acc Current Journal Review 11(6): 85-0, 2002

Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Human Gene Therapy. Clinical Development 24(1): 38-46, 2013

Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Human Gene Therapy 8(8): 985, 1997

Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Human Gene Therapy. Clinical Development 25(3): 164-177, 2014

A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Human Gene Therapy 11(3): 487-503, 2000